Library — CHDR

Search

Filter

Cognitive performance in healthy clinical trial participants and patients with the NeuroCart, a neurodegenerative disease measured with an automated neuropsychological and neurophysiological test battery.

Prins S, Borghans L, de Kam ML, Groeneveld GJ, van Gerven J

Journal of the neurological sciences, 2023 Jun

View publication
Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers.

Brooks S, Zuiker R, Bleys C, Ziagkos D, Moyer JA, van Nueten L, Bonaventure P, Drevets WC, van Gerven J, Salvadore G, Jacobs GE

Journal of psychopharmacology (Oxford, England), 2023 May

View publication
Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers.

Dijkstra F, O'Donnell P, Klaassen E, Buhl D, Asgharnejad M, Rosen L, Zuiker R, van Gerven J, Jacobs G

Translational psychiatry, 2022 Sep; 12(1):408

View publication
Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease.

Baakman AC, Gavan C, van Doeselaar L, de Kam M, Broekhuizen K, Bajenaru O, Camps L, Swart EL, Kalisvaart K, Schoonenboom N, Lemstra E, Scheltens P, Cohen A, van Gerven J, Groeneveld GJ

British journal of clinical pharmacology, 2022 Jun; 88(6):2814-2829

View publication
Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers.

Dijkstra FM, Zuiker RGJA, Siebenga PS, Leigh-Pemberton RA, Sun L, Manthis JD, de Kam ML, Lin R, von Moltke LL, Rezendes D, van Gerven JMA

British journal of clinical pharmacology, 2022 Jun; 88(6):2909-2925

View publication
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.

Berger B, Brooks S, Zuiker R, Richard M, Muehlan C, Dingemanse J

CNS drugs, 2021 Jun; 34(12):1253-1266

View publication
A Study of Novel Exploratory Tools, Digital Technologies, and Central Nervous System Biomarkers to Characterize Unipolar Depression.

Sverdlov O, Curcic J, Hannesdottir K, Gou L, De Luca V, Ambrosetti F, Zhang B, Praestgaard J, Vallejo V, Dolman A, Gomez-Mancilla B, Biliouris K, Deurinck M, Cormack F, Anderson JJ, Bott NT, Peremen Z, Issachar G, Laufer O, Joachim D, Jagesar RR, Jongs N, Kas MJ, Zhuparris A, Zuiker R, Recourt K, Zuilhof Z, Cha JH, Jacobs GE

Frontiers in psychiatry, 2021 Jun

View publication
Biperiden Challenge Model in Healthy Elderly as Proof-of-pharmacology Tool; A Randomized Placebo-controlled Trial.

Bakker C, van Esdonk MJ, Stuurman RFE, Borghans LAGJM, de Kam ML, van Gerven JMA, Groeneveld GJ

Journal of clinical pharmacology, 2021 May

View publication
Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M1‐acetylcholine receptor agonist: a randomized cross‐over trial

Bakker C, Prins S, Liptrot J, Hart EP, Klaassen ES, Brown GA, Brown A, Congreve M, Weir M, Marshall FH, Stevens J, Cross DM, Tasker T, Nathan PJ, Groeneveld GJ

BJCP, 2021 Apr

View publication

«
1
2
3
4
5
6
7
8
9
10
11
»